Price
$62.80-7.54%Social Signal Score
Analyst Ratings
42 analysts52-week range
- Last close
- $62.80
- Off 52w high
- -7.8%
- 200-day average
- $60.22
- vs 200-day
- +4.3%
Revenue
$13.07B+149.27%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher Boerner
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 32,500
- Beta
- 0.23
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.63
Financials
Revenue
$13.07B+149.3%Net Income
$2.16B+141.8%EBITDA
$2.94B+135.5%Free Cash Flow
$3.84B+263.0%EPS (diluted)
$1.05+98.1%Shares Outstanding (diluted)
2.05B+22.2%Operating Expenses
$4.06BCash & Debt
$12.58BReturn of Capital
$1.29BRevenue by Segment (annual)
$48.20BDividend per Share
$0.63Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $48.20B | $7.05B | $3.46 |
| 2024 | $48.30B | $-8.95B | $-4.41 |
| 2023 | $45.01B | $8.03B | $3.88 |
| 2022 | $46.16B | $6.33B | $2.97 |
| 2021 | $46.38B | $6.99B | $3.15 |
| 2020 | $42.52B | $-9.02B | $-3.98 |
| 2019 | $26.14B | $3.44B | $2.02 |
| 2018 | $22.56B | $4.92B | $3.03 |
| 2017 | $20.78B | $1.01B | $0.61 |
| 2016 | $19.43B | $4.46B | $2.67 |
| 2015 | $16.56B | $1.56B | $0.97 |
| 2014 | $15.88B | $2.00B | $1.21 |
| 2013 | $16.39B | $2.56B | $1.56 |
| 2012 | $17.62B | $1.96B | $1.17 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from BMY's reported EPS growth of 8.7% a year over 13 years.
- EPS in 5 years
- $5.24
- Implied price
- $83.92
- Return from $58.80
- 7.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $41.72 — -29.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| -1.3% | -8.0% | -5.1% | -2.5% | -0.2% | 1.9% |
| 3.7% | -3.3% | -0.3% | 2.4% | 4.9% | 7.1% |
| 8.7% | 1.4% | 4.5% | 7.4% | 9.9% | 12.3% |
| 13.7% | 6.0% | 9.4% | 12.3% | 15.0% | 17.4% |
| 18.7% | 10.7% | 14.2% | 17.3% | 20.0% | 22.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+600.00%Social Signal Score
Mentions (100)
- Newsfool.com·10h ago·Positive
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy for 2027? Bristol Myers Squibb maintains a powerful portfolio in oncology and hematology while trading at a low valuation multiple. Novo Nordisk dominates the rapidly expanding markets for obesity and diabetes treatments with high net margins.
View source ↗ - News247wallst.com·2d ago·Neutral
4 Dividend Stocks Wall Street Gave Up On With Balance Sheets Built to Recover When a stock falls out of favor, the balance sheet decides what happens to your income. A company with manageable debt and steady cash flow can keep paying shareholders while it repairs the business.
View source ↗ - News247wallst.com·3d ago·Negative
3 Big Pharma Dividend Stocks Built for Retirement Income Three drugmakers promise retirees steady paychecks, yet one faces a looming Eliquis cliff and two pay in foreign currencies that can shrink the check. Which dividend is safest when earnings look shaky but cash tells a different story?
View source ↗ - Newszacks.com·4d ago·Positive
Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy? MRK emerges as the stronger investment choice over BMY, backed by superior stock performance, oncology leadership, pipeline expansion and diversified growth drivers.
View source ↗ - Newsfool.com·4d ago·Positive
Bristol-Myers Squibb: 3 Key Takeaways for Long-Term Investors Growth portfolio revenue rose 12% year over year to $7.7 billion. Eight growth portfolio medicines annualized over $1 billion each.
View source ↗ - Newsbenzinga.com·4d ago·Neutral
Bristol Myers Squibb Says KarXT Reduces Hallucinations and Delusions In Preliminary Alzheimer's Trials Bristol Myers Squibb & Co. (NYSE:BMY) on Wednesday released preliminary Phase 3 data showing that short- and long-term KarXT treatment reduced symptoms in patients experiencing psychosis associated with Alzheimer's disease.
View source ↗ - Newszacks.com·4d ago·Neutral
Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline? MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.
View source ↗ - Newszacks.com·5d ago·Neutral
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newsfool.com·8d ago·Negative
Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story. Bristol Myers Squibb is a large and well-respected drug maker. The company is facing the normal industry headwind of patent expirations.
View source ↗ - Newszacks.com·9d ago·Neutral
Can BMY Sustain Growth in Its Cardiovascular Franchise? Bristol Myers Squibb is expanding Camzyos??? reach, benefiting from Eliquis?
View source ↗ - Newsreuters.com·10d ago·Neutral
Bristol Myers to merge scientific, clinical teams under new R&D structure Bristol Myers to merge scientific, clinical teams under new R&D structure
View source ↗ - Newsdefenseworld.net·12d ago·Negative
Bristol Myers Squibb Company $BMY Holdings Trimmed by AEGON ASSET MANAGEMENT UK Plc AEGON ASSET MANAGEMENT UK Plc trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 6.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 594,983 shares of the biopharmaceutical company's stock after selling 40,269 shares during the period. AEGON
View source ↗ - Newszacks.com·13d ago·Negative
Will Bristol Myers' Growth Brands Offset Eliquis Headwinds? Bristol Myers' Growth Portfolio drives 57% of revenues, with key brands gaining traction to offset legacy drug declines and support growth.
View source ↗ - Newsfool.com·15d ago·Negative
Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors The average pharmaceutical stock yields 1.4%, while Bristol Myers Squibb yields 4%. Bristol Myers Squibb is working through a transition period as older drugs lose patent protection.
View source ↗ - Newsbusinesswire.com·16d ago·Positive
Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AHA--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos.
View source ↗ - News247wallst.com·16d ago·Neutral
Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027? A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristol Myers Squibb's payout need to know which numbers actually matter before 2027 arrives.
View source ↗ - Newszacks.com·18d ago·Neutral
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - News (RSS)economictimes·19d ago·Positive
Wall Street's hidden bargains: 10 US largecap stocks trading at historic discount for investors At least 10 US large-cap stocks trade at 47%-63% discounts to sector valuations, according to Vested Finance. Comcast leads the list, alongside AT&T, Fiserv and Bristol-Myers Squibb, amid market volatility and growing scrutiny of AI valuations.
View source ↗ - Newszacks.com·20d ago·Positive
BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock? Bristol Myers Squibb gains 3% after beating third-quarter estimates, as its Growth Portfolio and promising pipeline support revenue prospects despite generic competition.
View source ↗ - Newsseekingalpha.com·23d ago·Negative
… The Patent Cliffs Remain (Rating Downgrade) Bristol-Myers Squibb is downgraded to 'Hold' as its current valuation appears optimistic ahead of looming patent cliffs. BMY's Growth Portfolio now comprises ~59% of revenues, with 8 medicines annualizing above $1 billion, partially offsetting legacy portfolio declines. DCF analysis values BMY at $61.19 per share, nearly matching the current price, highlighting limited upside even with near flat forward revenue growth.
View source ↗ - Newszacks.com·23d ago·Negative
BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress BMY raises its 2026 revenue outlook on strong Growth Portfolio sales, even as earnings pressure, patent expirations and drug launch challenges remain in focus.
View source ↗ - Newszacks.com·23d ago·Positive
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
View source ↗ - Newsmarketbeat.com·23d ago·Neutral
Bristol Myers Squibb Q3 Earnings Call Highlights Bristol Myers Squibb NYSE: BMY raised its full-year 2026 outlook after reporting third-quarter revenue growth supported by its growth portfolio and continued strength in ELIQUIS, while outlining a series of clinical readouts and manufacturing investments intended to support its next generation of launches.
View source ↗ - News (RSS)fool·24d ago·Positive
Bristol-Myers Squibb (BMY) Q3 2026 Earnings Call Transcript Eight growth medicines now each exceed $1 billion in annual sales.
View source ↗ - Newsfool.com·24d ago·Negative
Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction Bristol Myers Squibb's Growth Portfolio of newer drugs grew 12% to $7.7 billion in the third quarter, supplying nearly all of the company's 7% revenue gain to $13.1 billion. Adjusted EPS fell 17% to $1.35, but mostly because of deal accounting, not a weaker core business.
View source ↗ - Newszacks.com·24d ago·Neutral
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook Bristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript
View source ↗ - News (RSS)zerohedge·24d ago·Neutral
… PCE (8:30am). There are no Fed speakers scheduled; Treasury auctions $44 billion of 7-year notes at 1pm.Corporate events: Eli Lilly, Caterpillar, Mastercard, Merck, Bristol-Myers Squibb, Linde, Altria, ICE and Cheniere report before the bell; Amazon, Intel, Starbucks, Coinbase, Sandisk, Gilead, Reddit and Roblox report after the close. The ECB announces its decision at 9:15am ET, followed by Lagarde's press conference.Market SnapshotTop Overnight NewsA global rally in technology shares stalled …
View source ↗ - Newszacks.com·24d ago·Positive
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat Estimates Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.63 per share a year ago.
View source ↗ - Newswsj.com·24d ago·Neutral
Bristol Myers Squibb Raises Outlook as Quarterly Revenue Rises Bristol Myers Squibb raised its full-year revenue outlook due to higher third-quarter revenue.
View source ↗ - Newsfool.com·26d ago·Negative
Bristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression — Here's Why It Matters It also demonstrated very promising results when evaluated in other solid tumors. The company's involvement in the program is part of a broader effort to develop its burgeoning growth portfolio.
View source ↗ - Newszacks.com·27d ago·Negative
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings? Bristol-Myers Squibb heads into Q3 earnings with growth drugs and higher Eliquis guidance offsetting legacy portfolio declines.
View source ↗ - Newsmarketbeat.com·27d ago·Negative
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock Bristol Myers Squibb TodayBMYBristol Myers Squibb$61.20 -0.28 (-0.45%) As of 01:50 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$42.52▼$68.64Dividend Yield4.12%P/E Ratio13.48Price Target$65.50Add to WatchlistGLP-1 agonists may have taken up most of the attention when it comes to game-changing drugs in the last couple of years, but the oncology landscape is heating …
View source ↗ - Newsfool.com·27d ago·Positive
Bristol Myers Squibb: Bargain Buy or Value Trap? The healthcare stock trades at a forward earnings multiple of just nine, and its growth rate has been in the low single digits this year.
View source ↗ - Newszacks.com·27d ago·Neutral
Bristol Myers (BMY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures Get a deeper insight into the potential performance of Bristol Myers (BMY) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
View source ↗ - Newsbusinesswire.com·27d ago·Negative
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung.
View source ↗ - Newsfool.com·28d ago·Negative
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings? Bristol Myers Squibb is set to lose patent protections on two blockbuster drugs. Wall Street appears worried that it won't develop new drugs in time to offset the revenue hit from patent losses.
View source ↗ - News (Marketaux)manilatimes.net·28d ago·Positive
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy who have progressed on an immunotherapy-[+328 characters]
View source ↗ - Newszacks.com·30d ago·Negative
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know Bristol Myers Squibb (BMY) reached $61.48 at the closing of the latest trading day, reflecting a -2.41% change compared to its last close.
View source ↗ - News (RSS)financialpost·30d ago·Neutral
…force the potential for immune reset with zolacabtagene autoleucel to address an underlying cause of multiple sclerosis PRINCETON, N.J. — Bristol Myers Squibb (NYSE: BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohorts of the Phase 1, single-arm, dose-escalation Breakfree-2 study evaluating zolacabtagene autoleucel (zola-cel; BMS-986353), an […]
View source ↗ - Newsbenzinga.com·30d ago·Positive
What's Going On with Bristol Myers Squibb Stock on Friday? Bristol Myers Squibb & Co. (NYSE:BMY) stock is trading lower on Friday after the company reported one patient death in an investigational CD19-directed CAR T cell therapy trial.
View source ↗ - Newszacks.com·30d ago·Negative
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? Bristol Myers edges out AbbVie with a cheaper valuation and higher dividend yield, but pipeline execution, legacy drug declines and debt remain key risks.
View source ↗ - Newsreuters.com·30d ago·Negative
Bristol Myers, SystImmune drug cuts breast cancer progression risk in study Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
View source ↗ - Newsfool.com·31d ago·Positive
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. Bristol-Myers Squibb (BMY -0.91%) earns most of its revenue by commercializing complex prescription medications for cancer, cardiovascular conditions, and immunological diseases.
View source ↗ - Newsseekingalpha.com·32d ago·Positive
Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings On October 27, Bristol-Myers Squibb will report its results for Q3. As a reminder, its Q2 revenue rose 12.9% quarter-on-quarter to $12.97 billion, primarily due to the strong performance of Camzyos and the oncology portfolio. On October 12, BMS reported that Phase 3 ACTION-1 met its primary endpoint, significantly improving PFS with RYZ101 in SSTR+ GEP-NET patients.
View source ↗ - News (RSS)fool·36d ago·Positive
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.
View source ↗ - Newsfool.com·37d ago·Positive
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? Bristol-Myers Squibb offers a deep focus on oncology and hematology with a favorable valuation. Johnson & Johnson provides a diversified mix of innovative medicine and a massive medical technology division.
View source ↗ - News247wallst.com·37d ago·Negative
Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increases on a collision course with the drugs Wall Street is betting everything on.
View source ↗ - News247wallst.com·39d ago·Neutral
These 4 Dividend Stocks Passed the 2020 Stress Test. Are They Buys in Now October? Four companies kept raising their dividends even as the pandemic hammered their sectors in 2020, and they are still raising today. The question is whether their yields and valuations make them worth buying right now.
View source ↗ - Newszacks.com·39d ago·Neutral
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newszacks.com·40d ago·Neutral
BMY Reports Mixed Phase III Trial Results, Stock Down Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs.
View source ↗ - Newszacks.com·41d ago·Negative
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today Bristol Myers Squibb (BMY) reached $57.6 at the closing of the latest trading day, reflecting a -2.58% change compared to its last close.
View source ↗ - Newsproactiveinvestors.com·41d ago·Negative
Bristol Myers falls 3% despite positive cancer drug trial results Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP) shares fell 3% to $57.39 after positive results from a late-stage trial of an experimental cancer treatment raised questions about the market's reaction to the announcement. The US drugmaker reported that its ACTION-1 Phase 3 trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for RYZ101 in pat…
View source ↗ - Newszacks.com·41d ago·Neutral
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock? Bristol Myers shares surge 35.8% as its Growth Portfolio and pipeline progress fuel momentum, but generic competition and valuation warrant caution.
View source ↗ - News (RSS)zerohedge·41d ago·Neutral
…in the wake of recent weakness. Biogen (BIIB) gains 4.1% as JPMorgan upgrades to overweight ahead of an increasingly compelling catalyst path in 2027. Bristol Myers (BMY) rises 4.4% after the drugmaker said a late-stage trial of a lower dose of its drug candidate for lung disease met its primary endpoint. CCC Intelligent Solutions (CCC) rises 11% as GTCR and Elliott Investment Management are said to be in advanced talks to acquire the car-insurance software provider. First Solar (FSLR) climbs 2.…
View source ↗ - Newsbusinesswire.com·41d ago·Neutral
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETs PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACTION--BMS Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101.
View source ↗ - Newsbusinesswire.com·41d ago·Positive
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ALOFT--Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint.
View source ↗ - Newsfool.com·43d ago·Positive
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance.
View source ↗ - Newsdefenseworld.net·43d ago·Negative
20,370 Bristol Myers Squibb Company $BMY Shares Bought by Apella Capital LLC Apella Capital LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 159.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,162 shares of the biopharmaceutical company's stock after purchasing an additional 20,370 shares during
View source ↗ - Newszacks.com·45d ago·Neutral
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report? Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - News (RSS)seekingalpha·45d ago·Neutral
Bristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An Opportunity
View source ↗ - Newsseekingalpha.com·46d ago·Positive
Bristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An Opportunity Bristol-Myers Squibb is reiterated as a buy, offering attractive valuation and a high 4.23% dividend yield. BMY delivered a strong Q2 earnings triple-play, raising FY 2026 sales guidance and demonstrating robust growth in both legacy and new products. Despite looming patent cliffs and projected EPS declines post-2026, BMY benefits from high free cash flow and recent bullish EPS revisions.
View source ↗ - Newsfool.com·46d ago·Positive
2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One) Bristol Myers Squibb is a pharmaceutical giant with a 100-year history and a 4.2% yield. Realty Income is a giant real estate investment trust with a 6% yield and a 31-year-long streak of annual dividend increases.
View source ↗ - Newszacks.com·46d ago·Negative
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward? Reblozyl's strong growth is helping Bristol Myers offset declining legacy drug sales, with new indications offering further upside.
View source ↗ - News (RSS)seekingalpha·47d ago·Neutral
Bristol-Myers Squibb: Patent Cliff Is Still A Problem
View source ↗ - Newszacks.com·48d ago·Neutral
BMY or ARGX: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newszacks.com·48d ago·Positive
Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
View source ↗ - Newszacks.com·48d ago·Positive
3 Stocks With Broker Rating Upgrades Amid Resilient Equity Markets Dollar General, Bristol-Myers and Equinor stand out after broker rating upgrades, backed by projected earnings growth and resilient U.S. equity markets.
View source ↗ - News (Marketaux)insidermonkey.com·49d ago·Neutral
AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy? (NYSE:ABBV) closed at $262.82 on October[+350 characters]
View source ↗ - Newsfool.com·50d ago·Positive
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? Bristol Myers has faced patent cliffs in recent years, and there are more on the horizon. The company seems relatively well equipped to deal with this issue moving forward.
View source ↗ - Newszacks.com·51d ago·Positive
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio? Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.
View source ↗ - Newsfool.com·52d ago·Neutral
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale Johnson & Johnson generates consistently higher quarterly revenue than Bristol-Myers Squibb, maintaining a clear lead in total dollars over the entire observed eight-quarter period without any interruption. Both companies experienced a gentle pattern of quarter-over-quarter revenue growth over the last two calendar years, though the exact quarterly figures occasionally fluctuated between consecutive reporting periods.
View source ↗ - Newsbusinesswire.com·53d ago·Negative
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients* PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--U.S. FDA Approves Expanded Indication for BMS's CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients.
View source ↗ - News247wallst.com·53d ago·Negative
Bristol Myers Squibb's Dividend Sustainability Hinges on One Critical Cash Flow Metric Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff on its biggest cash generator puts that streak on a collision course with reality in 2027.
View source ↗ - Newszacks.com·53d ago·Neutral
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newsfool.com·54d ago·Negative
3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation Bristol Myers Squibb's stock price is up 42.5% in the past 12 months, yet it still trades at a discounted valuation. Investors remain uncertain about the company's efforts to replace legacy drug sales with the sale of new drug products.
View source ↗ - Newsfool.com·56d ago·Positive
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? Bristol Myers Squibb's Growth Portfolio sales rose 15% in the second quarter, and management raised its 2026 revenue guidance to $49 billion to $50 billion. Novo Nordisk expects 2026 adjusted sales to range from flat to down 6% at constant exchange rates, even after raising that outlook in August.
View source ↗ - Newsseekingalpha.com·57d ago·Positive
Buy 5 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' September DiviDogs Long-term bond yields persist despite pressure and circular remedies. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” —Barron's Weekly reported in October 2024. It's still true more than ever as 10-yr bonds yield >5%. Interviewed by Barron's, Steven Wieti
View source ↗ - Newszacks.com·59d ago·Negative
Why Women-Run Companies Deserve a Place in Your Portfolio BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.
View source ↗ - Newszacks.com·59d ago·Negative
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY? Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.
View source ↗ - Newszacks.com·59d ago·Positive
New Strong Buy Stocks for September 24th BMY, HRTG, RDVT, NMR and ECO have been added to the Zacks Rank #1 (Strong Buy) List on September 24th, 2026.
View source ↗ - Newszacks.com·59d ago·Positive
Best Income Stocks to Buy for September 24th ECO, NMR, BMY made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 24th, 2026.
View source ↗ - News247wallst.com·60d ago·Negative
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions.
View source ↗ - Newszacks.com·62d ago·Neutral
BMY vs GILD: Which Biotech Stock Looks More Attractive Now? Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
View source ↗ - Newszacks.com·62d ago·Positive
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsfool.com·63d ago·Neutral
Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder Bristol Myers Squibb's stock is up more than 17% so far this year. The company could be acquired by AstraZeneca.
View source ↗ - Newszacks.com·65d ago·Positive
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects? Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.
View source ↗ - Newszacks.com·65d ago·Neutral
BMY vs. ARGX: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Bristol Myers Squibb (BMY) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newsbusinesswire.com·65d ago·Neutral
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026 PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026.
View source ↗ - Newszacks.com·66d ago·Positive
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know Bristol Myers Squibb (BMY) closed the most recent trading day at $62.84, moving 1.19% from the previous trading session.
View source ↗ - Newszacks.com·67d ago·Neutral
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newsfool.com·70d ago·Positive
Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone? Patent cliff concerns continue to weigh down Bristol Myers Squibb's stock. The pharmaceutical company's management is taking active steps to counter some longstanding headwinds.
View source ↗ - News (Marketaux)finance.yahoo.com·71d ago·Positive
How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year? Our analysts combed the entire stock mar[+254 characters]
View source ↗ - News247wallst.com·71d ago·Negative
How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year? The exercise is simple: how large a position in Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction) do you need to throw off $10,000 a year in dividend income? Start with the income target and solve backward, using the live
View source ↗ - Newszacks.com·73d ago·Negative
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors Bristol Myers Squibb (BMY) reached $63.75 at the closing of the latest trading day, reflecting a -1.02% change compared to its last close.
View source ↗ - Newszacks.com·73d ago·Positive
BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock? Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its legacy portfolio warrants caution.
View source ↗ - Newszacks.com·74d ago·Neutral
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion? Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.
View source ↗ - Newsseekingalpha.com·78d ago·Positive
Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum Growth assets now comprise 58.2% of Bristol Myers Squibb Company's revenues, with the legacy portfolio also reporting a promising deceleration in top-line erosion cadence. The successful Opdivo/Qvantig conversion and the upcoming launches like iberdomide/mezigdomide target significant multiple myeloma market opportunities. The raised FY2026 guidance and productivity initiatives drive top-line/margin expansion, with the r
View source ↗ - Newszacks.com·79d ago·Neutral
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.
View source ↗ - Newszacks.com·79d ago·Positive
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.
View source ↗
Earnings
Thu, Feb 4(in 2 months)
Consensus estimate $1.53 per share
Typical surprise +20.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$1.35 vs $1.10beat
- Thu, Jul 30$2.04 vs $1.60beat
- Thu, Apr 30$1.58 vs $1.42beat
- Thu, Feb 5$1.26 vs $1.23beat
- Thu, Oct 30$1.63 vs $1.52beat
- Thu, Jul 31$1.46 vs $1.09beat
Estimates and results for BMY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BMY officers and directors.
- Bought
- —
- Sold
- $2.5m
0 trades
5 trades
- Haller Julia Asold
- Massacesi Cristiansold
- Holzer Phil Msold
- Elkins David Vsold
- Elkins David Vsold
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (27d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (33d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (477d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Mike Kellyhouse · PA16 · disclosed Jun 12, 2026 (36d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$15,001 - $50,000
- Julie Johnsonhouse · TX32 · disclosed Jan 16, 2026 (29d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (447d later)Buy$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (260d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 12, 2026 (24d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Dec 15, 2025 (33d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Dec 12, 2025 (29d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 18, 2025 (40d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (28d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Sep 12, 2025 (29d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (318d later)Buy$1,001 - $15,000
- Virginia Ann Foxxhouse · NC05 · disclosed Jul 4, 2025 (10d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$15,001 - $50,000
- Thomas Hawley Tubervillesenate · AL · disclosed May 15, 2025 (30d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
